Q: I know you guys are not warm and fuzzy about these guys and don't follow them anymore, but for some reason I find them, let's say, "interesting". Their CIRO trading halt order is a week and a half old now with no news. This is obviously due to their late filings. It's either going to be really good or really bad. Do you have a wild guess and opinion?
Q: I hold Gardant in a riff. I am down 70% on the name. I am thinking of selling to look for better opportunities. Could I have your opinion please. Thank you.
Q: 1. has well ever been in a profit since inception if so what year and what was the EPS. that year. .2. what is the EPS projection for WELL for 2024 year . 3. what is the projection for EPS for 2025 year. 4. what is the share count for years ended 2022 and 2023. 5. have the insiders been buying more shares at depressed market prices or just exercising options at lower prices and selling.into the market thanks Richard
Q: Hi 5i
Hum down 15% today after earnings and a poor guidance.....also CVS down ...What is your opinion on HUM and what does the future look like for these companies....short term/long term.
Is this industry in trouble?
Where do you see things go from here and a what price does this company become attractive investment.
Q: I expect many will ask but I'll join the crowd anyways- what do you folks think about the release today? They seem to be doing, "well." I thought the organic growth was a good sign...
Q: Thoughts on the quarter and would you be a buyer here? Interesting reaction to the earnings though- it was up in AH trading but is basically unchanged now. Is it too expensive?
I am wondering about the merit of purchasing NBLY shares prior to the deal close in order to acquire the Contingent Value Rights (CVR). My thinking is that this would require a short term commitment of capital that could potentially yield a payout in 2026. How likely is it that the EBITDA Target of $128M will be met? If one were to proceed with this strategy when would the shares need to be purchased?
Q: GILD is down 10% after its phase 3 trial of Trodelvy in a lung cancer trial failed to meet its primary end-point. Is this just "noise" or a reason for a long-term shareholder to sell?
Q: The news on well health has been good lately; how is it that analysts all of a sudden lower their ratings.. It makes me wonder if there is some manipulation going on unless they are seeing Well not as attractive all of a sudden. Your responses of late have been positive and i know opinions can differ. Can you shed some light please?